The findings were consistent in patients switched to Angiox monotherapy from unfractionated heparin or Sanofi-Aventis's Lovenox (enoxaparin). The Medicines Company recently re-acquired rights for Angiox in Europe and
In the study – a randomized, double-blind, placebo-controlled clinical trial – patients were assigned to four weeks of treatment with either Lilly's investigational compound LY2140023; olanzapine, an atypical
The proof-of-concept study of 147 patients with primary insomnia showed that almorexant significantly improves the primary parameter of sleep efficiency (time spent sleeping while confined to bed during
The drug, called interferon alpha (IFNa), is used to clean up microscopic tumor cells that may remain in the body following surgery for the disease. It is the
The drug, known as ACAM2000, is the first biodefence vaccine to be approved as part of the US response to the 2001 bioterrorism attacks. Acambis developed ACAM2000 under
The double-blinded placebo-controlled study included 281 patients, males and females aged 18-65, with a BMI ranging from 30 to 40. The study was conducted at 19 investigation sites
The document, which reviews current data on Isentress (raltegravir), said that “the benefits of raltegravir in HIV-1 treatment-experienced subjects outweigh the currently identified risks.” The drug is currently
The first trial showed that in patients with acute ST-segment elevation myocardial infarction (STEMI) treated with fibrinolysis, at one year, the primary endpoint of death or nonfatal myocardial
The single pill would target all three major blood lipids – LDL-C “bad” cholesterol, HDL-C “good” cholesterol, and triglycerides, and combines Abbott’s next-generation fenofibrate ABT-335, which is currently
The combination drug contains Merck-developed extended-release niacin and laropiprant – a novel flushing pathway inhibitor. Cordaptive lowered LDL-cholesterol (LDL-C) levels, increased HDL-cholesterol (HDL-C) levels and reduced triglyceride levels
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.